TABLE 3.
Modeled performance of CTX-M/KPC/NDM to predict nonsusceptible E. coli, Klebsiella species, and Proteus mirabilis across different prevalences of resistancea
| Resistance (%) | No. of VMEb | Ceftriaxone |
TZP |
Meropenem |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VME (n) | LCL | UCL | VME (n) | LCL | UCL | VME (n) | LCL | UCL | ||
| 5 | 0 | 1.03 | 0.23 | 1.19 | 1.33 | 1.28 | 1.37 | 0.39 | 0.23 | 0.65 |
| 10 | 0 | 2.07 | 0.47 | 2.38 | 2.65 | 2.57 | 2.74 | 0.79 | 0.47 | 1.30 |
| 15 | 0 | 3.10 | 0.70 | 3.57 | 3.98 | 3.85 | 4.11 | 1.18 | 0.70 | 1.95 |
| 20 | 0 | 4.13 | 0.93 | 4.76 | 5.31 | 5.14 | 5.48 | 1.58 | 0.93 | 2.60 |
| 25 | 0 | 5.16 | 1.17 | 5.95 | 6.64 | 6.42 | 6.85 | 1.97 | 1.17 | 3.25 |
| 30 | 0 | 6.20 | 1.40 | 7.14 | 7.96 | 7.70 | 8.22 | 2.36 | 1.40 | 3.90 |
| 35 | 0 | 7.23 | 1.63 | 8.33 | 9.29 | 8.99 | 9.59 | 2.76 | 1.63 | 4.55 |
| 40 | 0 | 8.26 | 1.86 | 9.52 | 10.62 | 10.27 | 10.96 | 3.15 | 1.86 | 5.20 |
| 45 | 0 | 9.29 | 2.10 | 10.71 | 11.95 | 11.56 | 12.33 | 3.55 | 2.10 | 5.86 |
| 50 | 1 | 10.33 | 2.33 | 11.90 | 13.27 | 12.84 | 13.71 | 3.94 | 2.33 | 6.51 |
a
LCL, lower confidence limit; UCL, upper confidence limit; TZP, piperacillin-tazobactam; VME, very major error (total number expected per 100 isolates tested).
b
The number of VME accepted by the FDA.